The St. Louis-based firm submitted a stand-alone Drug Master File with the U.S. Food and Drug Administration, along with an Active Substance Master File with the European Medicines Agency, for its germanium-68 agent.

Engaging in such thought patterns over a long period of time could raise an individual's chance of developing the brain disease, according to a new study.

Tauvid was developed by Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, and offers clinicians a new type of brain scan to use in patients being evaluated for Alzheimer's disease.

The radiopharmaceutical—Cerianna—is the first F-18 agent approved for use in patients with recurrent or metastatic breast cancer.

Stony Brook University investigators seek to quantify the precise degree of brain inflammation in those with the illness and ultimately hope to suggest novel treatments.

German scientists found six of seven patients with difficult-to-treat cancer had genetic mutations in their DNA damage-repair genes, according to new research.

Vancouver, British Columbia-based Artms will use the funding to help bolster the supply of locally produced radioisotopes, such as technetium-99m.

Inflitration occurs when a a radiotracer is not safely injected into an individual's vein, but the true impact of these adverse events remains unknown to patients and physicians.